Sucralfate
Brand name: Carafate
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Active duodenal ulcer — short-term treatment | Adults | Monotherapy | FDA Approved |
| Duodenal ulcer — maintenance therapy | Adults | Monotherapy | FDA Approved |
Sucralfate is a locally acting mucosal protectant approved specifically for duodenal ulceration. Its efficacy in duodenal ulcer healing has been shown to be comparable to histamine H2-receptor antagonists in controlled trials. Treatment duration for active ulcers is typically 4 to 8 weeks, with maintenance dosing available for recurrence prevention. The drug does not alter the underlying disease course or prevent future recurrences.
Stress ulcer prophylaxis in ventilated ICU patients — Evidence quality: Moderate. Some data suggest reduced nosocomial pneumonia risk compared to acid-suppressive agents, though PPIs have largely supplanted sucralfate in contemporary practice.
GERD in pregnancy — Evidence quality: Low. ACG guidelines list sucralfate as an option during pregnancy given its negligible systemic absorption.
Hemorrhagic radiation proctitis (sucralfate enema) — Evidence quality: Moderate. ASCRS guidelines acknowledge sucralfate retention enemas as an effective option for chronic radiation proctitis with rectal bleeding.
Oral mucositis from chemotherapy/radiation — Evidence quality: Low. Limited evidence for benefit; some oncology protocols include sucralfate swish-and-spit for oropharyngeal mucositis.
NSAID-related dyspepsia and gastric erosions — Evidence quality: Low. Data suggest symptom improvement similar to H2 blockers, but PPIs are generally preferred.
Topical wound healing (venous ulcers, burns) — Evidence quality: Low. Case series suggest benefit through growth factor potentiation, but large controlled trials are lacking.
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Active duodenal ulcer — healing phase | 1 g QID | 1 g QID for 4–8 weeks | 4 g/day | Administer on empty stomach, 1 h before meals and at bedtime Continue for 4–8 wk unless healing confirmed by endoscopy |
| Duodenal ulcer — maintenance / recurrence prevention | 1 g BID | 1 g BID | 2 g/day | Initiated after successful healing phase Optimal maintenance duration not established beyond 1 year |
| Stress ulcer prophylaxis — mechanically ventilated patients (off-label) | 1 g QID | 1 g QID | 4 g/day | Via nasogastric tube; administer as suspension PPIs/H2RAs now more commonly used in most ICU protocols |
| GERD symptom relief in pregnancy (off-label) | 1 g QID | 1 g QID | 4 g/day | On empty stomach; may be used when antacids insufficient ACG guideline-supported option in pregnancy |
| Radiation proctitis — rectal administration (off-label) | 2 g paste enema | 2 g enema BID | 4 g/day (rectal) | 2 tablets crushed in 4.5 mL water as paste; retain for 30 min Per ASCRS clinical practice guidelines |
Special Population Adjustments
| Population | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Elderly | 1 g QID | 1 g BID–QID | 4 g/day | Start cautiously; monitor renal function and concomitant medications Aluminum accumulation risk increases with declining renal function |
| Renal impairment / Dialysis | Use with extreme caution or avoid | Aluminum does not cross dialysis membranes; accumulation and toxicity reported Monitor serum aluminum if used; consider alternative agents | ||
| Pediatric | Safety and efficacy not established | Not FDA-approved for pediatric use Off-label topical use studied in post-adenotonsillectomy analgesia | ||
Sucralfate must be taken on an empty stomach — at least 1 hour before meals — because food and gastric acid activate the drug’s polymerization. Concomitant medications should be given at least 2 hours before sucralfate to avoid binding-related absorption reduction. Antacids, if needed for pain, should be separated by at least 30 minutes.
Pharmacology
Mechanism of Action
Sucralfate is a basic aluminum salt of sucrose octasulfate that works through a local, non-systemic mechanism. In the acidic gastric environment (pH <4), sucralfate undergoes cross-linking and polymerization to form a viscous, paste-like substance. This gel adheres selectively to ulcerated mucosa by binding to positively charged proteins in the ulcer exudate, creating a physical barrier that shields the lesion from acid, pepsin, and bile salts. The drug also inhibits pepsin activity by approximately 32% at therapeutic doses and adsorbs bile salts that would otherwise damage healing tissue. Beyond its barrier properties, sucralfate stimulates local prostaglandin synthesis, which enhances bicarbonate secretion and mucus production. It also binds epidermal growth factor and fibroblast growth factor, concentrating these mediators at the ulcer site and promoting tissue regeneration. Each gram of sucralfate provides approximately 14–16 mEq of acid-neutralizing capacity, though this is not considered its primary therapeutic mechanism.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | <5% systemically absorbed; onset of action 1–2 h | Predominantly local effect; systemic adverse reactions uncommon |
| Distribution | Distributes to GI mucosal lesions; no significant systemic distribution | Drug remains concentrated at the ulcer site; no CNS or peripheral tissue effects expected |
| Metabolism | Degraded locally in GI tract to aluminum + sucrose octasulfate; not hepatically metabolized | No CYP-mediated metabolic interactions; no hepatic dose adjustment needed |
| Elimination | Small absorbed fraction excreted renally; bulk excreted in feces | Aluminum clearance depends on renal function — accumulation risk in CKD/dialysis patients |
Side Effects
Sucralfate has a favorable safety profile owing to its negligible systemic absorption. In clinical trials involving over 2,700 patients, adverse effects were reported in 4.7% overall. The most clinically significant concern is constipation.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| No adverse effects reported at ≥10% incidence in clinical trials (FDA PI) | ||
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Constipation | 2% | Most frequently reported adverse effect; related to aluminum content; manage with adequate fluid intake and fiber |
The following were reported in fewer than 0.5% of patients in clinical trials: diarrhea, dry mouth, flatulence, gastric discomfort, indigestion, nausea, vomiting, pruritus, rash, dizziness, insomnia, sleepiness, vertigo, back pain, and headache.
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Aluminum toxicity (osteodystrophy, encephalopathy) | Rare | Weeks to months with chronic use in renal impairment | Discontinue sucralfate; check serum aluminum; consider deferoxamine chelation |
| Gastric bezoar formation | Rare | Weeks to months; higher risk with enteral feeds or gastroparesis | Discontinue; may require endoscopic removal; avoid in patients with delayed gastric emptying |
| Anaphylaxis / hypersensitivity (edema of mouth, lips, pharynx, urticaria, dyspnea) | Very rare | Minutes to hours after first or subsequent doses | Emergency treatment; permanent discontinuation; document allergy |
| Hypophosphatemia | Rare | Weeks of chronic use | Monitor phosphate levels; supplement if needed; consider discontinuation |
| Hyperglycemia (in diabetic patients using suspension) | Rare | Days after initiation | Increase blood glucose monitoring; adjust antidiabetic therapy as needed |
| Fatal pulmonary/cerebral emboli (with inadvertent IV administration) | Very rare | Immediate | NEVER administer intravenously — oral/enteral route only |
Constipation is the most clinically relevant adverse effect of sucralfate, attributable to its aluminum content. Encourage patients to maintain adequate hydration (1.5–2 L/day) and dietary fiber intake. An osmotic laxative such as polyethylene glycol may be added if constipation persists. Patients with pre-existing constipation or gastroparesis should be monitored closely, as they are also at increased risk of bezoar formation.
Drug Interactions
Sucralfate interacts with other drugs primarily through a non-systemic binding mechanism in the GI tract, not through hepatic CYP enzyme pathways. It physically adsorbs co-administered medications, reducing their bioavailability. In virtually all studied cases, separating the interacting drug by at least 2 hours before sucralfate eliminates the interaction.
The overwhelming majority of sucralfate drug interactions can be managed with a simple timing strategy: give the interacting medication at least 2 hours before sucralfate. This separation window has been validated in pharmacokinetic studies for cimetidine, ciprofloxacin, digoxin, norfloxacin, ofloxacin, and ranitidine. When a patient takes multiple medications, careful scheduling of sucralfate at the end of the dosing window is the most practical approach.
Monitoring
-
Renal Function
Baseline; periodically in at-risk patients
Routine Serum creatinine and estimated GFR before initiation. Particularly important in elderly patients and those with known CKD, as aluminum accumulation risk increases with declining renal clearance. -
Serum Aluminum
If CKD or dialysis patient
Trigger-based Monitor serum aluminum levels in patients with renal impairment, especially dialysis patients. Elevated levels warrant discontinuation and possible chelation with deferoxamine. -
Blood Glucose
Ongoing in diabetic patients
Trigger-based The oral suspension contains glucose and may cause hyperglycemia in diabetic patients. Monitor blood glucose more frequently when initiating sucralfate suspension and adjust antidiabetic therapy as needed. -
Serum Phosphate
Periodically with chronic use
Trigger-based Aluminum-containing compounds can bind dietary phosphate. Check serum phosphate if patient develops weakness, bone pain, or is on prolonged therapy, particularly in malnourished or CKD populations. -
Ulcer Healing
Endoscopy at 4–8 weeks
Routine Healing should be confirmed by endoscopy or radiography. If ulcer persists after 8 weeks of therapy, reassess diagnosis and consider alternative treatments including testing for H. pylori. -
Drug Levels (interacting medications)
As clinically indicated
Trigger-based Monitor levels or clinical effect of narrow-therapeutic-index drugs given concurrently (phenytoin, digoxin, warfarin/INR, levothyroxine/TSH) when starting, adjusting, or stopping sucralfate.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to sucralfate or any excipient — anaphylactic reactions have been reported post-marketing
- Intravenous administration — fatal pulmonary and cerebral emboli have occurred with inadvertent IV use; sucralfate must only be given orally or enterally
Relative Contraindications (Specialist Input Recommended)
- End-stage renal disease / dialysis — aluminum accumulation and toxicity (osteodystrophy, encephalopathy) are well-documented; aluminum does not cross dialysis membranes. Consider alternative mucosal protective agents.
- Patients on multiple narrow-therapeutic-index drugs — the extensive binding interactions may be difficult to manage with timing alone in complex medication regimens. Coordination with pharmacy is recommended.
Use with Caution
- Chronic kidney disease (non-dialysis) — monitor serum aluminum and renal function periodically
- Diabetes mellitus — the oral suspension contains glucose; hyperglycemia has been reported. Close glycemic monitoring recommended.
- Dysphagia or impaired gag/cough reflex — risk of aspiration with oral suspension
- Delayed gastric emptying / gastroparesis — increased risk of bezoar formation
- Enteral tube feeding — bezoar formation risk is higher with concurrent tube feeds; the tube may also become occluded
- Elderly patients — more likely to have reduced renal function and polypharmacy; start at conservative end of dosing range
Fatal complications including pulmonary and cerebral emboli have been reported with inappropriate intravenous administration of sucralfate oral suspension. Sucralfate must be administered only by the oral route. Healthcare facilities should ensure that sucralfate is clearly labeled for oral/enteral use only and stored separately from injectable medications to prevent inadvertent IV administration.
Patient Counselling
Purpose of Therapy
Sucralfate works by forming a protective coating over your ulcer, shielding it from stomach acid so it can heal. It does not reduce the amount of acid your stomach produces — it provides a physical barrier. Treatment typically lasts 4 to 8 weeks for active ulcers, and your doctor may then switch you to a lower maintenance dose to help prevent recurrence.
How to Take
Take sucralfate on an empty stomach, ideally 1 hour before meals and at bedtime. If you are using the liquid suspension, shake the bottle well before each dose. Do not freeze the suspension. Take sucralfate at the same times each day. If you are taking other medications, take them at least 2 hours before your sucralfate dose to ensure they are absorbed properly.
Sources
- Carafate (sucralfate) Oral Suspension — FDA-Approved Prescribing Information, revised December 2022. Allergan USA, Inc. FDA Label (Suspension) Current FDA-approved label for sucralfate oral suspension; source for approved indications, dosing, adverse reactions, and contraindications.
- Carafate (sucralfate) Tablets — FDA-Approved Prescribing Information, revised 2013. Aptalis Pharma US, Inc. FDA Label (Tablets) FDA-approved label for sucralfate tablets; includes maintenance dosing (1 g BID) and clinical trial healing rate data.
- Garnett WR. Sucralfate — alternative therapy for peptic-ulcer disease. Clin Pharm. 1982;1(4):307–314. PubMed: 6764389 Early clinical review establishing sucralfate efficacy as comparable to cimetidine and intensive antacid therapy for duodenal ulcer healing.
- Driks MR, Craven DE, Celli BR, et al. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. N Engl J Med. 1987;317(22):1376–1382. PubMed: 2891032 Landmark trial showing reduced nosocomial pneumonia with sucralfate for stress ulcer prophylaxis compared to pH-raising agents.
- Kochhar R, Patel F, Dhar A, et al. Radiation-induced proctosigmoiditis: prospective, randomized, double-blind controlled trial. Dig Dis Sci. 1991;36(1):103–107. PubMed: 1670631 RCT demonstrating superiority of rectal sucralfate over oral sulfasalazine for short-term treatment of radiation proctitis.
- Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022;117(1):27–56. DOI: 10.14309/ajg.0000000000001538 ACG guideline listing sucralfate as a treatment option for GERD during pregnancy.
- Paquette IM, Vogel JD, Abbas MA, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Treatment of Chronic Radiation Proctitis. Dis Colon Rectum. 2018;61(10):1135–1140. PubMed: 30192320 ASCRS guideline supporting sucralfate retention enemas as effective treatment for rectal bleeding from chronic radiation proctitis.
- Ye Z, Reintam Blaser A, Lytvyn L, et al. Gastrointestinal bleeding prophylaxis for critically ill patients: a clinical practice guideline. BMJ. 2020;368:l6722. PubMed: 31907223 BMJ clinical practice guideline on GI bleeding prophylaxis in ICU; contextualizes sucralfate’s role relative to PPIs and H2RAs.
- McCarthy DM. Sucralfate. N Engl J Med. 1991;325(14):1017–1025. PubMed: 1886624 Comprehensive NEJM review of sucralfate’s mechanism of action, covering cytoprotective effects, growth factor binding, and prostaglandin stimulation.
- Masuelli L, Tumino G, Turriziani M, et al. Topical use of sucralfate in epithelial wound healing: clinical evidences and molecular mechanisms of action. Recent Pat Inflamm Allergy Drug Discov. 2010;4(1):25–36. PubMed: 19832693 Review of sucralfate’s wound-healing properties including FGF and EGF binding that underpin its off-label topical applications.
- Sulochana SP, Syed M, Chandrasekar DV, et al. Clinical Drug-Drug Pharmacokinetic Interaction Potential of Sucralfate with Other Drugs: Review and Perspectives. Eur J Drug Metab Pharmacokinet. 2016;41(5):469–503. PubMed: 27086359 Comprehensive review of sucralfate’s drug interaction profile with pharmacokinetic data for each documented interaction.
- Hemstreet BA. Use of sucralfate in renal failure. Ann Pharmacother. 2001;35(3):360–364. PubMed: 11261535 Evaluates aluminum accumulation risk from sucralfate in patients with renal impairment; supports caution or avoidance in dialysis patients.
- Steiner K, Bühring KU, Faro HP, et al. Sucralfate: pharmacokinetics, metabolism and selective binding to experimental gastric and duodenal ulcers in animals. Arzneimittelforschung. 1982;32(5):512–518. PubMed: 6896647 Foundational pharmacokinetic study demonstrating minimal systemic absorption and selective ulcer-site binding of sucralfate.